Page 97 - 《中国药房》2021年16期

[11] LEE M C，LIAO C T，TOH H S，et al. Cost-effectiveness 121（1）：293-298.
analysis of low-dose rivaroxaban plus aspirin for the pa- [25] HAYDEN M，PIGNONE M，PHILLIPS C，et al. Aspirin
tients with stable cardiovascular disease in Taiwan set- for the primary prevention of cardiovascular events：a
ting[J]. Value Health，2019，22：168. summary of the evidence for the US preventive services
[12] ADEMI Z，ZOMER E，TONKIN A，et al. Cost-effective- task force[J]. Ann Intern Med，2002，136（2）：161-172.
ness of rivaroxaban and aspirin compared to aspirin alone [26] EIDELMAN R S，HEBERT P R，WEISMAN S M，et al.
in patients with stable cardiovascular disease：an Australian An update on aspirin in the primary prevention of cardio-
perspective[J]. Int J Cardiol，2018，270：54-59. vascular disease[J]. Arch Intern Med，2003，163（17）：
[13] SHIFFMAN D，SLAWSKY K，FUSFELD L，et al. Cost- 2006-2010.
effectiveness model of use of genetic testing as an aid in [27] LEWIS E F，LI Y，PFEFFER M A，et al. Impact of cardio-
assessing the likely benefit of aspirin therapy for primary vascular events on change in quality of life and utilities in
prevention of cardiovascular disease[J]. Clin Ther，2012， patients after myocardial infarction：a VALIANT study
34（6）：1387-1394. （valsartan in acute myocardial infarction）[J]. JACC Heart
[14] GREVING J P，BUSKENS E，KOFFIJBERG H，et al. Fail，2014，2（2）：159-165.
Cost-effectiveness of aspirin treatment in the primary pre- [28] JAMISON D T，BREMAN J G，MEASHAM A R，et al.
vention of cardiovascular disease events in subgroups Disease control priorities in developing countries[M]. 2nd
based on age，gender，and varying cardiovascular risk[J]. ed. Washington，DC：World Bank，2006：1.
Circulation，2008，117（22）：2875-2883. [29] AUGUSTOVSKI F A，CANTOR S B，THACH C T，et al.
[15] PIGNONE M，EARNSHAW S，PLETCHER M J，et al. Aspirin for primary prevention of cardiovascular events[J].
Aspirin for the primary prevention of cardiovascular di- J Gen Intern Med，1998，13（12）：824-835.
sease in women：a cost-utility analysis[J]. Arch Intern [30] PIGNONE M，EARNSHAW S，TICE J A，et al. Aspirin，
Med，2007，167（3）：290-295. statins，or both drugs for the primary prevention of coro-
[16] MARSHALL T. The cost-effectiveness of drug treatments nary heart disease events in men：a cost-utility analysis[J].
for primary prevention of cardiovascular disease：a model- Ann Intern Med，2006，144（5）：326-336.
ling study[J]. Eur J Prev Cardiol，2006，13（4）：523-528. [31] NAGLIE I G，DETSKY A S. Treatment of chronic nonval-
[17] LAMOTTE M，ANNEMANS L，EVERS T，et al. A cost- vular atrial fibrillation in the elderly：a decision analy-
effectiveness analysis of low-dose aspirin in the primary sis[J]. Med Decis Making，1992，12（4）：239-249.
prevention of cardiovascular disease in four European [32] POST P N，STIGGELBOUT A M，WAKKER P P. The
countries[J]. Value Health，2005，8（6）：98. utility of health states after stroke：a systematic review of
[18] EIKELBOOM J W，CONNOLLY S J，BOSCH J，et al. the literature[J]. Stroke，2001，32（6）：1425-1429.
Rivaroxaban with or without aspirin in stable cardiovascu- [33] NIKOLIC E，JANZON M，HAUCH O，et al. Cost-effec-
lar disease[J]. N Engl J Med，2017，377（14）：1319-1330. tiveness of treating acute coronary syndrome patients with
[19] 梁岩，朱俊，谭慧琼，等.中国地区非ST抬高急性冠脉综 ticagrelor for 12 months：results from the PLATO
合征患者生存时间的影响因素分析[J].中华医学杂志， study[J]. Eur Heart J，2013，34（3）：220-228.
2005，85（13）：873-878. [34] LATIMER N，LORD J，GRANT R L，et al. Cost effective-
[20] 武海滨，龚巍巍，潘劲，等.首次脑卒中患者生存率和死亡 ness of COX 2 selective inhibitors and traditional
影响因素的研究[J].中华流行病学杂志，2014，35（7）： NSAIDs alone or in combination with a proton pump in-
812-816. hibitor for people with osteoarthritis[J]. BMJ，2009，339：
[21] LAMOTTE M，ANNEMANS L，EVERS T，et al. A 62538.
multi-country economic evaluation of low-dose aspirin in [35] NHERERA L，CALVERT N W，DEMOTT K，et al.
the primary prevention of cardiovascular disease[J]. Phar- Cost-effectiveness analysis of the use of a high-intensity
macoeconomics，2006，24（2）：155-169. statin compared to a low-intensity statin in the manage-
[22] BERGER J S，RONCAGLIONI M C，AVANZINI F，et al. ment of patients with familial hypercholesterolaemia[J].
Aspirin for the primary prevention of cardiovascular Curr Med Res Opin，2010，26（3）：529-536.
events in women and men：a sex-specific meta-analysis of [36] 王玲，符杨丽，钟薇.医院老年人阿司匹林一级预防心血
randomized controlled trials[J]. JAMA，2006，295（3）： 管疾病现状调查与分析[J].中国药业，2019，28（11）：
306-313. 123-125.
[23] MININO A M，SMITH B L. Deaths：preliminary data for [37] 王熙明.心血管疾病患者二级预防药物治疗依从性对预
2000[J]. Natl Vital Stat Rep，2001，49（12）：491-531. 后的影响[J].中国卫生标准管理，2017，8（4）：76-77.
[24] ANDERSON K M，ODELL P M，WILSON P W，et al. （收稿日期：2021-02-28 修回日期：2021-07-27）
Cardiovascular disease risk profiles[J]. Am Heart J，1991， （编辑：孙 冰）

中国药房 2021年第32卷第16期 China Pharmacy 2021 Vol. 32 No. 16 ·2007 ·